Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Madrigal Pharmaceuticals Inc is a biotechnology business based in the US. Madrigal Pharmaceuticals shares (MDGL) are listed on the NASDAQ and all prices are listed in US Dollars. Madrigal Pharmaceuticals employs 42 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$79.35|
|52-week range||$76.03 - $142.62|
|50-day moving average||$81.08|
|200-day moving average||$100.68|
|Wall St. target price||$170.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-14.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-5.00%|
|1 month (2021-09-21)||1.16%|
|3 months (2021-07-21)||-15.23%|
|6 months (2021-04-21)||-38.19%|
|1 year (2020-10-21)||-37.56%|
|2 years (2019-10-21)||-9.71%|
|3 years (2018-10-19)||192.48|
|5 years (2016-10-21)||366.76%|
|Gross profit TTM||$0|
|Return on assets TTM||-40.67%|
|Return on equity TTM||-75.39%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
There are currently 1.4 million Madrigal Pharmaceuticals shares held short by investors – that's known as Madrigal Pharmaceuticals's "short interest". This figure is 0.2% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Madrigal Pharmaceuticals shares can be evaluated.
Madrigal Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Madrigal Pharmaceuticals shares currently shorted divided by the average quantity of Madrigal Pharmaceuticals shares traded daily (recently around 108650.03750938). Madrigal Pharmaceuticals's SIR currently stands at 13.33. In other words for every 100,000 Madrigal Pharmaceuticals shares traded daily on the market, roughly 13330 shares are currently held short.
However Madrigal Pharmaceuticals's short interest can also be evaluated against the total number of Madrigal Pharmaceuticals shares, or, against the total number of tradable Madrigal Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Madrigal Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Madrigal Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.173% of the tradable shares (for every 100,000 tradable Madrigal Pharmaceuticals shares, roughly 173 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Madrigal Pharmaceuticals.
Find out more about how you can short Madrigal Pharmaceuticals stock.
We're not expecting Madrigal Pharmaceuticals to pay a dividend over the next 12 months.
Madrigal Pharmaceuticals's shares were split on a 1:35 basis on 24 July 2016. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Madrigal Pharmaceuticals shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Madrigal Pharmaceuticals shares which in turn could have impacted Madrigal Pharmaceuticals's share price.
Over the last 12 months, Madrigal Pharmaceuticals's shares have ranged in value from as little as $76.03 up to $142.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Madrigal Pharmaceuticals's is 1.1312. This would suggest that Madrigal Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.